Downregulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 enhances the sensitivity of human pancreatic cancer cells to radiotherapy in vitro

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 2, 2013, Pages 169-176

  Chen, Sumei ^a,b   Xiong, Guangsu ^a   Wu, Shuming ^a   Mo, Jianzhong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

APE1 Ref 1; pancreatic cancer; radiotherapy; siRNA

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CHROMIUM PHOSPHATE P 32; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; MESSENGER RNA; REDOX EFFECTOR FACTOR 1; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIZATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE; RADIOSENSITIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMIUM COMPOUNDS; COLONY-FORMING UNITS ASSAY; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; FLOW CYTOMETRY; HUMANS; PANCREATIC NEOPLASMS; PHOSPHATES; PHOSPHORUS RADIOISOTOPES; RADIATION TOLERANCE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84874718458     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1266     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277.
2. Haller DG. Future directions in the treatment of pancreatic cancer. Semin Oncol 2002;29(6 Suppl. 20):31.
3. Moertel CG, Frytak S, Hahn RG. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group. Cancer 1981;48:1705.
4. Westlin JE, Andersson-Forsman C, Garske U, et al. Objective responses after fractionated infusional brachytherapy of unresectable pancreatic adenocarcinomas. Cancer 1997;80(12 Suppl.):2743.
5. Kakolyris S, Kaklamanis L, Engels K, et al. Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. Br J Cancer 1998;77:1169.
6. Evans AR, Limp-Foster M, Kelley MR. Going APE over ref-Mutat Res 2000 461: 83
7. Bobola MS, Blank A, Berger MS, et al. Apurinic/ apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res. 2001;7:3510.
8. Tell G, Damante G, Caldwell D, Kelley MR. The intracellular localization of APE1/Ref-1: More than a passive phenomenon? Antioxidants Redox Signal 2005;7:367.
9. Fishel ML, Kelley MR. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 2007;28:375.
10. Fleck O, Nielsen O. DNA repair. J Cell Sci 2004;117(Pt 4):515.
11. Xiong GS, Sun HL, Wu SM, Mo JZ. Small interfering RNA against the apurinic or apyrimidinic endonuclease enhances the sensitivity of human pancreatic cancer cells to gemcitabine in vitro. J Dig Dis 2010;11:224.
12. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev 2001;15:188.
13. Elbashir SM, Martinez J, Patkaniowska A, et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001;20:6877.
14. Lau JP, Weatherdon KL, Skalski V, Hedley DW. Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. Br J Cancer 2004;91:1166.
15. Bobola MS, Finn LS, Ellenbogen RG, et al. Apurinic/ apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin Cancer Res 2005;11:7405.
16. Fung H, Demple B. A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells. Mol Cell 2005;17:463.
17. Silber JR, Bobola MS, Blank A, et al. The apurinic/ apyrimidinic endonuclease activity of Apel/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin Cancer Res 2002;8:3008.
18. Bobola MS, Emond MJ, Blank A, et al. Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy. Clin Cancer Res 2004;10:7875.
19. Herring CJ, West CML, Wilks DP, et al. Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers. Br J Cancer 1998;78:1128.
20. Herring CJ, Deans B, Elder RH, et al. Expression levels of the DNA repair enzyme HAP1 do not correlate with the radiosensitivities of human or HAP1-transfected rat cell lines. Br J Cancer 1999;80:940.
21. Madhusudan S, Smart F, Shrimpton P, et al. Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res 2005;33:4711.
22. Parsons JL, Dianova, II, Dianov GL. APE1 is the major 3- phosphoglycolate activity in human cell extracts. Nucleic Acids Res 2004;32:3531.
23. Luo M, Kelley MR. Inhibition of the human apurinic/ apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res 2004;24:2127.
24. Taverna P, Liu L, Hwang HS, et al. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat Res 2001;485:269.
25. Liu L, Nakatsuru Y, Gerson SL. Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res 2002; 8:2985.
26. Rinne M, Caldwell D, Kelley MR. Transient adenoviral Nmethylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells. Mol Cancer Ther 2004;3:955.
27. Tell G, Quadrifoglio F, Tiribelli C, Kelley MR. The many functions of APE1/Ref-1: Not only a DNA repair enzyme. Antioxid Redox Signal 2009;11:601.
28. Shimizu N, Sugimoto K, Tang J, et al. High-performance affinity beads for identifying drug receptors. Nat Biotechnol 2000;18:877.
29. Zou GM, Luo MH, Reed A, et al. Ape1 regulates hematopoietic differentiation of embryonic stem cells through its redox functional domain. Blood 2007;109:1917.
30. Zou GM, Maitra A. Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol Cancer Ther 2008;7:2012.
31. Zou GM, Karikari C, Kabe Y, et al. The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: Therapeutic implications in tumor angiogenesis. J Cell Physiol 2009;219:209.
32. Raffoul JJ, Banerjee S, Singh-Gupta V, et al. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res 2007;67:2141.
33. El-Rayes BF, Philip PA, Sarkar FH, et al. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs 2010;29:694.
34. Ciolino HP, Daschner PJ, Yeh GC. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 1998;58:5707.
35. Jang M, Pezzuto JM. Effects of resveratrol on 12-Otetradecanoylphorbol- 13-acetate-induced oxidative events and gene expression in mouse skin. Cancer Lett 1998;134:81.
36. Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998;273:21875.
37. Kotha A, Sekharam M, Cilenti L, et al. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 2006;5:621.